O. N. Nefyodov
Research Subjects
O. N. Nefyodov has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Anastasiya I. Stukan
Kuban State Medical University, Ministry of Health of Russia
2 shared publications - Vladimir Alekseyevich Porkhanov
Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1; Kuban State Medical University
2 shared publications - A. G. Onishchenko
Clinical Oncology Dispensary No. 1
1 shared publication - A. V. Lapshin
Clinical Oncologic Dispensary No. 1
1 shared publication - A. Yu. Goryainova
Clinical Oncology Dispensary No. 1
1 shared publication - E. A. Nefyodova
Clinical Oncologic Dispensary No. 1
1 shared publication
Latest Publications
- 29 June 2026
- Published by "MedINK" Publishing House in Academy for Practical Oncology
- Vol. 1 (1)
Adenocystic cancer of minor salivary glands: peculiarities of clinical course
Adenoid cystic carcinoma of the minor salivary glands is a rare and aggressive form of malignant neoplasms characterized by hidden growth, rapid perineural advancement, tendency to develop local recurrences and distant metastases. This pathology is mostly seen in white women aged 50–60 years and is mostly localized in the sinonasal area and oral cavity. The article presents clinical cases of treatment of patients with adenoid cystic carcinoma of the sinonasal area and adenoid cystic carcinoma of the hard palate. Efficacy of off-label therapy as salvage therapy and an attempt to prolong life in incurable patients is demonstrated. Etiopathogenesis of this tumor is being investigated, and new treatment strategies are being developed, including targeted therapies.
- 29 June 2026
- Published by "MedINK" Publishing House in Academy for Practical Oncology
- Vol. 1 (1)
Adenocystic cancer of minor salivary glands: peculiarities of clinical course
Adenoid cystic carcinoma of the minor salivary glands is a rare and aggressive form of malignant neoplasms characterized by hidden growth, rapid perineural advancement, tendency to develop local recurrences and distant metastases. This pathology is mostly seen in white women aged 50–60 years and is mostly localized in the sinonasal area and oral cavity. The article presents clinical cases of treatment of patients with adenoid cystic carcinoma of the sinonasal area and adenoid cystic carcinoma of the hard palate. Efficacy of off-label therapy as salvage therapy and an attempt to prolong life in incurable patients is demonstrated. Etiopathogenesis of this tumor is being investigated, and new treatment strategies are being developed, including targeted therapies.
- Open Access
- 14 October 2022
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 12 (3) , 114-126
Adaptive immune response in pathogenesis and treatment of head and neck squamous cell carcinoma: the influence of immunosuppression factors and gender
An obvious trend of the last decade in head and neck squamous cell carcinoma pathogenesis evaluation is awareness of the impact of immune response disorders on disease manifestation. The review presents an analysis of the differences in the type and degree of immunosuppression, as well as treatment response in head and neck squamous cell carcinoma patients in accordance with influencing carcinogenic factor, gender, age of the patient and concomitant diseases. An increase in CD8+ T-lymphocytes and a decrease of memory T-cells has been evaluated in smoking and alcohol abusing patients with head and neck squamous cell carcinoma, and a smaller number of CD8+ T-lymphocytes were detected in the tumor microenvironment compared to non-smoking and non-drinking patients. Studies have shown that the improved prognosis of patients with human papillomavirus (Hpv) – associated head and neck squamous cell carcinoma is largely due to the presence of antibodies against Hpv E6 and E7, E7-specific CD8+T lymphocytes in periphe ral blood and a high level of tumor-infiltrating T lymphocytes. The issue of gender differences in the type of immune response is widely discussed. It has been shown that the use of immune response checkpoint inhibitors is more effective in improving survival rates in men, and the use of these drugs in combination with chemotherapy is more effective in women. In addition, in elderly cancer patients, numerous age-associated T-lymphocyte’s function changes were revealed, including a decrease in the number of naive T-lymphocytes due to age-related involution of the thymus and an in crease in the relative number of memory cells and effector cells. Thus, it is clear that immunosuppression type, as well as treatment response, differ depending on the influencing factor, gender, age of the patient, as well as comorbidities.
- 14 October 2022
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 12 (3) , 114-126
Open AccessAdaptive immune response in pathogenesis and treatment of head and neck squamous cell carcinoma: the influence of immunosuppression factors and gender
An obvious trend of the last decade in head and neck squamous cell carcinoma pathogenesis evaluation is awareness of the impact of immune response disorders on disease manifestation. The review presents an analysis of the differences in the type and degree of immunosuppression, as well as treatment response in head and neck squamous cell carcinoma patients in accordance with influencing carcinogenic factor, gender, age of the patient and concomitant diseases. An increase in CD8+ T-lymphocytes and a decrease of memory T-cells has been evaluated in smoking and alcohol abusing patients with head and neck squamous cell carcinoma, and a smaller number of CD8+ T-lymphocytes were detected in the tumor microenvironment compared to non-smoking and non-drinking patients. Studies have shown that the improved prognosis of patients with human papillomavirus (Hpv) – associated head and neck squamous cell carcinoma is largely due to the presence of antibodies against Hpv E6 and E7, E7-specific CD8+T lymphocytes in periphe ral blood and a high level of tumor-infiltrating T lymphocytes. The issue of gender differences in the type of immune response is widely discussed. It has been shown that the use of immune response checkpoint inhibitors is more effective in improving survival rates in men, and the use of these drugs in combination with chemotherapy is more effective in women. In addition, in elderly cancer patients, numerous age-associated T-lymphocyte’s function changes were revealed, including a decrease in the number of naive T-lymphocytes due to age-related involution of the thymus and an in crease in the relative number of memory cells and effector cells. Thus, it is clear that immunosuppression type, as well as treatment response, differ depending on the influencing factor, gender, age of the patient, as well as comorbidities.